Aligos Therapeutics Profit Margin

Aligos Therapeutics (ALGS) currently reports a profit margin of -246.81% as of June 2026. That compares with -3894.17% in the prior-year period — up 93.7% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Aligos Therapeutics's profit margin history and peer comparisons.

Aligos Therapeutics's profit margin increased from -3894.17% to -246.81% — a 93.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aligos Therapeutics's profit margin of -246.81% is lower than the Healthcare sector average of 13.89%. That is roughly 1876.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Aligos Therapeutics's current -246.81% should be judged against Healthcare norms (sector average: 13.89%) and against ALGS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -246.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Aligos Therapeutics, and consider following ALGS for alerts when major investors trade the stock.